Ritonavir

Dosing

원내

HIV infection 600 mg PO q12hNo renal dose adjustment

원내

HIV infection If age >1m, 350-400 mg/BSA PO q12h (max 600 mg/dose)No renal dose adjustment

Mild or moderate hepatic impairment No dose adjustment

Severe hepatic impairment No data

General Information

Treatment of HIV infection.

Black Box Warning: Coadministration of ritonavir with several classes of drugs, including sedative hypnotics, antiarrhythmics or ergot alkaloid preparations, may result in life-threatening adverse events due to possible effects on the hepatic metabolism of certain drugs. Review medications taken by patients.

Monitor viral load prior to initiation or modification of treatment.

Monitor CD4 cell counts prior to initiation or with modification of ARV treatment and every 3-6 months; thereafter during at least the first 2 years of treatment.

Monitor hepatitis B screening at baseline and with modification of ARV treatment.

Perform hepatitis C antibody testing prior to initiation or modification of ARV treatment.

Monitor ALT,AST, and total bilirubin at baseline and with modification of ARV treatment.

Monitor CPK and uric acid levels at baseline and periodically during therapy.

Common

  • Edema

  • Flushing

  • Rash

  • Diarrhea

  • Nausea

  • Vomiting

  • Dizziness

  • Cough

  • Taste sense altered

Serious

  • Atrioventricular block

  • Prolonged PR interval

  • Syncope

  • Stevens-Johnson syndrome

  • Lipodystrophy

  • Diabetes mellitus

  • Hyperglycemia

  • Hemorrhage

  • Neutropenia

  • Hepatic failure

  • Pancreatitis

  • Hepatitis

  • Increased liver enzymes

  • Hypersensitivity reaction

  • Anaphylaxis

  • Immune reconstitution syndrome

Multiple drug-drug interactions

Concomitant protease inhibitor: amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, tipranavir Inhibits: P450, CYP3A, CYP2D6

Antimicrobial class: Antiretroviral agent, Protease Inhibitor

Pregnancy category: B

Average serum half life: 3-5 hours

Precautions: Cardiac conduction abnormalities may occur; increased risk in patients with underlying structural disease, preexisting conduction system abnormalities, ischemic heart disease, cardiomyopathies, or concomitant use of PR-interval prolonging drugs; monitoring recommended.

Hepatotoxicity has been reported; risk factors include concomitant use of multiple medications, underlying hepatitis B or C, preexisting liver disease, liver enzyme abnormalities; monitoring recommended.

Lipid disorders, significant increases in total cholesterol and triglycerides, have been reported; monitoring recommended.

Consider monitoring for hyperglycemia and new onset or exacerbation of diabetes mellitus. Use of oral solution not recommended in preterm neonates in immediate postnatal period unless benefit outweighs risk.

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.